Exact, OncoMethylome Pen Two-Part Deal to Sell CRC-Screening Tests, Services in Europe, N. America | GenomeWeb
NEW YORK (GenomeWeb News) — OncoMethylome Sciences and Exact Sciences today said they plan to advance the sale of stool-based colorectal cancer-screening technologies through service labs in Europe and North America. 
 
The agreement calls for Exact to grant OncoMethylome non-exclusive rights to its DNA-stabilization, -isolation, and -extraction technology for stool-based CRC-screening tests in Europe.
 
In exchange, OncoMethylome will pay royalties to Exact based on sales.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.